Fritextsökning
Innehållstyper
-
The art of building a biologic drug
The first biosimilar from Xbrane Biopharma was launched earlier this year, and several more are under development at the company’s facility in Solna, Sweden. “W...
-
Suing the company – for NOT developing a new HIV drug
Was Gilead putting a steady flow of profits from its cash cow ahead of developing a new and safer drug? According to a large number of US HIV patients in a lega...
-
Founder of Bioarctic, Lars Lannfelt, is honoured: “I want to create something for the future”
It´s like a scientist’s dream: to be the world’s first with a drug that genuinely affects one of our major diseases. Lars Lannfelt and his company Bioarctic hav...
-
Webinar: Medtech quality and regulatory compliance
This webinar is for you who are developing or planning to develop a medical device, combination, or borderline product. In one hour, we will discuss what you ne...
-
Swedish and Ukrainian Medical Product Agencies sign an agreement
The Directors-General of the Swedish and Ukrainian Medical Products Agencies have signed a cooperation agreement.
-
Grönt ljus för Gesyntas endometriosstudie i Storbritannien – ”Ett stort steg”
Gesynta Pharma har fått klartecken i Storbritannien för att inleda en fas II-studie med sin läkemedelskandidat inom endometrios.
-
ZEISS Quality Innovation Days
The leading digital event from April 15-19, 2024.
-
Level up your medical expertise
Learn from innovative industry speakers from leading MedTech companies at ZEISS Quality Innovation Days.
-
The Swedish Research Council gets go-ahead for more long-term funding
Following a government decision, the Swedish Research Council will soon be able to approve ten-year grant periods for funding research infrastructure, which may...
-
The physician at the tech giant: “Observations in the emergency room made my mind up”
When Nasim Farrokhnia was in third grade at school in Tehran, the capital of Iran, her father gave her a book about Marie Curie, which soon became her favourite...
-
Tirzepatide approved for obesity by the FDA – to be branded as Zepbound
Diabetes drug tirzepatide has now also been approved in the US for treating obesity.
-
MedVasc and Scientific Solutions join forces to streamline FDA 510(k) regulatory process
MedVasc, an exciting MedTech startup company, and Scientific Solutions, a renowned consulting firm within Life Science, are pleased to announce a strategic part...
-
Study: Cancer vaccine prolongs survival in difficult-to-treat tumour disease
According to a new study, a combination of a cancer vaccine from Norwegian company Ultimovacs and two immunotherapies significantly prolonged survival in cases ...
-
Marie Gårdmark: Potential step change – EU regulators get to play with data
A new pilot from EMA is starting in September to assess wether the analysis of 'raw data' by regulatory authorities improves the evaluation of marketing approva...
-
Science to Market - S2M
-
Ossiform: Quality control of 3D printed bone implants
Ossiform chose the GOM Scan 1.
-
EXCL Gantry Kit Improve Automated Lab Applications
We’re excited to introduce a new product that improves precision and throughput in life science applications. The EXCL multi-axis gantry kit lowers engineering ...
-
“A major energy boost for the entire cancer vaccine field”
The development of cancer vaccines has accelerated in recent years. Norwegian Ultimovacs is one of the companies attempting to develop a new type of treatment l...
-
Charlotta Gummeson leaves Sahlgrenska Science Park – “It feels sad and exciting at the same time”
With mixed emotions, Charlotta Gummeson will leave her position as CEO of Sahlgrenska Science Park in October. “It feels sad and exciting at the same time. I’ve...
-
ZEISS Quality Innovation Days: April 15 – 19, 2024
Be there when industry experts give exciting insights into different applications and trends in 90 minutes on various theme days.
-
Catalent kapar bort 350 tjänster inom genterapi
CDMO-bolaget Catalent säger upp 350 av sina anställda inom genterapiproduktion i USA.
-
The Swedish government is to increase its investment in cancer care
The Swedish government wants to invest more in cancer and paediatric cancer care and proposes to allocate SEK 500 million per year for this purpose in the coming years.
-
ZEN core now available for all ZEISS scanning electron microscopes
Introducing intuitive, streamlined SEM control over imaging, analytics, and multi-modal workflows.
-
Mathias Uhlén’s protein atlas is recognised as a global resource
The Human Protein Atlas is the first database in Sweden to be designated a Global Core Biodata Resource. According to Mathias Uhlén, this is a quality hallmark ...